PMID- 29100396
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 44
DP  - 2017 Sep 29
TI  - Combination therapy of human umbilical cord mesenchymal stem cells and FTY720 
      attenuates acute lung injury induced by lipopolysaccharide in a murine model.
PG  - 77407-77414
LID - 10.18632/oncotarget.20491 [doi]
AB  - ALI/ARDS remain the main reason of morbidity and mortality in the critically ill. 
      Studies have indicated that human umbilical cord mesenchymal stem cells 
      (hUC-MSCs) can be useful in the treatment of ALI/ARDS. Sphingosine-1-phosphate 
      (S1P) and its analog FTY720 significantly reduce lipopolysaccharide (LPS)-induced 
      lung edema and inflammatory lung injury. This study aimed to assess the 
      therapeutic effects of hUC-MSCs combined with FTY720 in an LPS-induced murine 
      model of ALI. Eight-week-old female C57BL/6 mice were divided into a normal 
      control group, an LPS group, an hUC-MSC group, an FTY720 group, and an 
      hUC-MSCs+FTY720 group randomly. At 24 hours post injury, mice were administrated 
      hUC-MSCs via the tail vein and/or intraperitoneally injected with FTY720. We 
      assessed histopathology and histologic scores, lung wet/dry weight ratio, 
      micro-CT scans, and total protein in the bronchoalveolar lavage fluid (BALF), as 
      well as cytokines in the BALF at 48 h post injury. All treatment groups showed 
      higher survival rates and attenuated lung injuries. The hUC-MSCs+FTY720 group 
      yielded better results than hUC-MSCs or FTY720 alone. While the underlying 
      mechanism requires further study, we anticipate that combination therapy of 
      hUC-MSCs and FTY720 could be an effective strategy for ALI.
FAU - Zhang, Zili
AU  - Zhang Z
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
AD  - Anhui Medical University, Hefei 230032, China.
AD  - Beijing Geriatric Hospital, Beijing 100095, China.
FAU - Li, Wenfei
AU  - Li W
AD  - School of Aerospace Medicine, Fourth Military Medical University, Xi'an 710032, 
      China.
FAU - Heng, Zhizhi
AU  - Heng Z
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Zheng, Jing
AU  - Zheng J
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Li, Puyuan
AU  - Li P
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Yuan, Xin
AU  - Yuan X
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Niu, Wenkai
AU  - Niu W
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Bai, Changqing
AU  - Bai C
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
FAU - Liu, Huiying
AU  - Liu H
AD  - Department of Respiratory and Critical Care Diseases, 307th Hospital of PLA, 
      Beijing 100071, China.
LA  - eng
PT  - Journal Article
DEP - 20170824
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5652788
OTO - NOTNLM
OT  - FTY720
OT  - Sphingosine-1-phosphate
OT  - acute lung injury
OT  - hUC-MSCs
OT  - lipopolysaccharide
COIS- CONFLICTS OF INTEREST The authors declare that they have no competing interests.
EDAT- 2017/11/05 06:00
MHDA- 2017/11/05 06:01
PMCR- 2017/09/29
CRDT- 2017/11/05 06:00
PHST- 2017/06/01 00:00 [received]
PHST- 2017/07/26 00:00 [accepted]
PHST- 2017/11/05 06:00 [entrez]
PHST- 2017/11/05 06:00 [pubmed]
PHST- 2017/11/05 06:01 [medline]
PHST- 2017/09/29 00:00 [pmc-release]
AID - 20491 [pii]
AID - 10.18632/oncotarget.20491 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 24;8(44):77407-77414. doi: 10.18632/oncotarget.20491. 
      eCollection 2017 Sep 29.